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Objective: Family history is an independent risk factor for premature acute myocardial infarction; in contrast, familial risk
for peripheral arterial disease (PAD) has yet to be determined. Elevated levels of hemostatic proteins are consistently
predictive for cardiovascular risk in “healthy” subjects, and may cluster with underlying insulin resistance. Atherothrom-
botic risk factor clustering occurs in first-degree relatives of subjects with coronary artery disease and type 2 diabetes.
These may contribute to the enhanced cardiovascular risk in these subjects, and we hypothesised that familial clustering
may occur in PAD. The objective of this study was to measure atherothrombotic risk factors in healthy male first-degree
relatives of men with intermittent claudication, with emphasis on thrombotic risk.
Methods: One hundred sixty-five healthy male first-degree relatives were compared with control subjects matched for age,
sex, and race (n  165), free from a personal or family history of premature cardiovascular disease. Primary outcome
measures were fibrinogen, von Willebrand factor, factor VII clotting activity (FVII:C), and factor XIII levels. Athero-
sclerotic risk factors were measured, and subjects were genotyped for common functional polymorphisms (factor VII
r353q and fibrinogen B -455).
Results: Relatives had higher mean levels of fibrinogen (3.04 vs 2.89 g/L; P  .021), FVII:C (117% vs 104%; P  .000),
factor XIII B subunit (1.11 vs 1.01 IU/mL; P  .000), and complex (A2B2; 1.18 vs 1.11 IU/mL; P  .021). At
multivariate analysis the association between relative status and fibrinogen, FVII:C, and factor XIII B subunit levels were
independent of other variables.
Conclusions: The healthy male relatives of men with PAD have elevated levels of fibrinogen, factor VII, and factor XIII.
Our results support the existence of thrombotic risk factor clustering in this population at “high risk.” (J Vasc Surg
2004;40:891-8.)Atherosclerosis is a generalized disorder that culmi-
nates in plaque formation and superimposed thrombosis.
Although plaque composition primarily determines vulner-
ability to disruption,1 many studies indicate that perturbed
hemostasis has a pivotal role in atherothrombosis. In
“healthy” subjects elevated levels of fibrinogen,2,3 factor
VII,4 and von Willebrand factor (vWF)5 independently
predict for the incidence of acute myocardial infraction
(AMI). More recently associations between factor XIII and
type 2 diabetes,6 coronary artery disease (CAD), and AMI7
have been reported. Insulin resistance is an adverse meta-
bolic state characterized by clustering of multiple athero-
genic risk factors8 that constitute insulin-resistance syn-
drome. Elevated levels of key hemostatic proteins have
been described in association with insulin resistance,9 and
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Further studies have established family history as an
independent risk factor for premature CAD,10,11 and her-
itability studies support the causal involvement of genetic
factors.12,13 The familial nature of peripheral arterial dis-
ease (PAD) has yet to be investigated in an epidemiologic
study. Recent small studies, however, have shown a high
prevalence of cardiovascular disease (CVD)14 and occult
PAD15 in first-degree relatives of subjects with premature
PAD. Atherothrombotic risk factor clustering occurs in
first-degree relatives of subjects with CAD16-18 and type 2
diabetes,6,19 and may contribute to their enhanced cardio-
vascular risk. We hypothesised that male first-degree rela-
tives of men with intermittent claudication cluster multiple
atherothrombotic risk factors. The purpose of this study
was to measure these factors, with emphasis on thrombotic
risk.
METHODS
This case-control family study was carried out at the
United Leeds Teaching Hospitals NHS Trust and the
Huddersfield NHS Hospital Trust, West Yorkshire, United
Kingdom. All study subjects were recruited from the gen-
eral population within the geographic location of West
Yorkshire.
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Leeds Teaching Hospitals NHS Trust and the Hudders-
field NHS Hospital local research ethics committees.
Sample size. A priori sample size calculations were
performed for all primary outcome measures, but ulti-
mately were factor VII–dependent. One hundred sixty-five
subjects were required per group to demonstrate a 10%
difference in factor VII levels for 80% power at the 5%
significance level.
Subjects. One hundred eight subjects with intermit-
tent claudication (probands) were identified from consec-
utive patients attending the vascular outpatient depart-
ment. All were white men younger than 65 years. All
probands had intermittent claudication as defined by the
Edinburgh Claudication Questionnaire,20 with stable
symptoms for more than 6 months, and ankle-brachial
pressure index (ABPI) less than 0.8. Review of the clinical
notes showed that 60 patients (56%) had atherosclerotic
PAD confirmed at angiography, and 48 patients (44%) had
atherosclerotic pad confirmed at duplex scanning. Subjects
with critical limb ischemia were excluded to maintain the
homogeneity of the study population. Overall, 50 patients
(45%) had concomitant CVD, and 52 patients (48%) had
undergone previous peripheral vascular intervention (Table
I). Of these subjects, 20 (18.5%) underwent angioplasty or
stenting, 27 (25.0%) underwent open surgical intervention,
and 5 (4.6%) underwent both radiologic and surgical inter-
vention.
From these probands 165 male first-degree relatives
were recruited, of whom 37 (22.4%) were brothers and 128
(77.6%) were sons. In light of known sex differences in
hemostatic parameters, only male subjects were recruited,
to maximize recruitment and maintain the power of the
study. All first-degree relatives were between 18 and 65
years of age, and were free from clinical CVD and known
diabetes. These were compared with control subjects
Table I. Clinical characteristics of male patients with
intermittent claudication (probands)
Patients with intermittent
claudication
Age (y) 62 (57,65)*
Age at diagnosis (y) 54 (50,60)*
Claudication distance (m) 200 (100,250)*
Ankle-brachial pressure index 0.64*
Peripheral vascular interventions 52 of 108 (48%)
Angioplasty or stenting 20/108 (18.5%)
Surgical endarterectomy or
bypass†
27/108 (25%)
Both radiologic and surgical
intervention
5/108 (4.5%)
Coexistent cardiovascular disease‡ 50/108 (46%)
Co-existent diabetes 24/108 (22%)
*Nonparametric data expressed as median (25th, 75th quartiles).
†Bypass (aortoiliac, femorofemoral, femoropopliteal) or common femoral
endarterctomy.
‡Coronary artery disease, cerebrovascular disease.matched for age, sex, and race recruited at random from theLeeds Family Health Authorities Register. All control sub-
jects were free from clinical CVD, diabetes, and a family
history of CVD (defined as65 years for the purpose of the
study).
Clinical assessment. All subjects provided informed
consent, per protocol approved by the relevant local
research ethics committee. All subjects fasted for 10
hours overnight, and were asked to refrain from smoking
during this time. All subjects were free from both inter-
mittent claudication and angina, according to Edin-
burgh Claudication20 and Rose Angina Question-
naires.21 A detailed medical history was taken, including
drug history and consumption of nicotine and alcohol.
Blood pressure was determined with an automated cuff
to the nearest 2 mm Hg, and taken as the mean of 3
readings. Body mass index (BMI) was calculated as
weight in kilograms divided by height-squared in meters
(kg/m2). Waist-hip ratio (WHR) was calculated as min-
imal abdominal girth (to the nearest 0.5 cm) divided by
maximal protrusion of the hips (in centimeters) at the
level of the symphysis pubis. Twelve-lead electrocardiog-
raphy was performed to exclude myocardial ischemia or
previous infraction. Resting ABPI was measured in both
legs with a hand-held 8-MHz Doppler probe (Handy-
dop; SciMed) over the infragenicular arteries. ABPI of
less than 0.9 is 95% sensitive in detecting angiogram-
positive disease, and ABPI 0.9 or greater is almost 100%
specific in detecting “healthy” subjects.22 All subjects
with ABPI less than 0.9 were excluded from the study.
Fifty milliliters of free-flowing venous blood was drawn
from an antecubital vein with a 19-gauge needle. Blood
was transferred to a room temperature lithium heparin
tube for plasma lipid profile, lithium fluoride for plasma
glucose assay, ethylenediamine tetraacetic acid for de-
oxyribonucleic acid extraction, and sodium citrate for
hemostatic proteins. A pre-cooled lithium heparin tube
was used for plasma insulin assay, and was transferred
immediately onto ice. All subjects underwent a 75-g oral
glucose tolerance test, and plasma glucose concentration
was determined at 2 hours. Glycemic state was classified
in accordance with World Health Organization crite-
ria.23
Laboratory methods. Sample tubes at room temper-
ature were centrifuged at 3000g (MSE; Sanyo Gallenkamp)
for 20 minutes. Iced samples were centrifuged at 4000g for
30 minutes in a pre-cooled centrifuge (Coolspin; Fisons
Scientific) at 4° C. Plasma aliquots were snap-frozen in
liquid nitrogen before being placed in long-term storage at
40° C. All assays were performed in duplicate, and mean
levels were calculated. Plasma fibrinogen was measured
with the Clauss method.1 Factor VII clotting activity
(FVII:C) was performed on an ACL 300 Plus (Instrumen-
tation Laboratory) with factor VII–deficient plasma
(Sigma) and recombinant rabbit thromboplastin (Instru-
mentation Laboratories). Levels are expressed as a percent-
age of activity given by calibration plasma (FVII:C [%]).
vWF antigen levels were determined with an enzyme-linked
immunosorbent assay with commercially available antibod-
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antigen levels were determined with an enzyme-linked
immunosorbent assay as described.2 The interassay and
intra-assay coefficients of variation for fibrinogen, FVII:C,
vWF, factor XIII B subunit, and factor XIII A2B2 were 3.5%
and 2%, 3.2% and 3.2%, 4.7% and 2.8%, 9.8% and 6.2%, and
9.3% and 5.4%, respectively. Human insulin was measured
with an immunoassay (Medgenix-Ins-Easia; (Biosource
Europe), and the interassay and intra-assay coefficients of
variance were 3.5% and 2.5%, respectively. Insulin resis-
tance was estimated with Homeostasis Model Assessment
(HOMA), In which insulin resistance  Fasting glucose
(mmol/L) Fasting insulin (IU/mL)/22.5. This assumes
that healthy subjects with normal weight and younger than
35 years have 100% B-cell function and insulin resistance of
unity.26
Genomic DNA was extracted from leukocytes with a
nucleon DNA extraction kit (Nucleon Biosciences). Geno-
typing was performed for common polymorphisms known
to influence hemostatic protein levels, including the fibrin-
ogen -455 G/A (classified G/G, G/A, or A/A)3 and
factor VII R353q polymorphisms (classified G/G, G/A,
and A/A).4 Plasma glucose was measured with the glucose
oxidase method, total cholesterol and triglyceride levels
with a Hitachi 747 automatic analyzer (Boehringer-Mann-
heim), high-density lipoprotein cholesterol with a Hitachi
717 automatic analyzer (Boehringer-Mannheim), and low-
density lipoprotein cholesterol with the Friedewald equa-
tion.
Statistical methods. Parametric data are presented
as mean (standard deviation), log-normal data as geo-
metric mean (anti-logged 95% confidence intervals),
nonparametric data as median (25th, 75th percentiles),
and categorical data as a proportion (%). An independent
Student t test was used to assess for a difference in means,
Mann-Whitney U test for a difference in ranks, and 2
test for difference in proportions between study groups.
One-way analysis of variance was used to compare hemo-
static protein levels according to genotype. Bivariate
correlation was used to establish association between
hemostatic proteins and other continuous variables.
Pearson correlation coefficients () were calculated if
both variables were normally distributed, and the Spear-
man rank coefficient () was calculated if one or more
variables were nonparametric. Forward stepwise multiple
linear regression was used to assess for association be-
tween hemostatic protein level and relative status, ad-
justing for significant correlates. Only covariates that
independently predicted hemostatic protein levels were
included in the final model. The exclusion of nonsignif-
icant correlates did not affect the variance explained by
the model (R2). Adjusted levels of hemostatic protein
levels were calculated, allowing for confounding vari-
ables. All analyses were performed by one of the authors
(D.J.P.) with SPSS for Windows, version 9.0, and P 
.05 was considered statistically significant.RESULTS
Clinical and biochemical characteristics
The clinical characteristics of the probands are shown in
Table I. Both the first-degree relatives and control subjects
were similar in age, alcohol intake, and anthropometric
characteristics (Table II). Conversely, the relatives clus-
tered multiple atherogenic risk factors, including higher
systolic blood pressure, plasma cholesterol, low-density
lipoprotein cholesterol, triglycerides, fasting insulin, and
estimated insulin resistance, and higher prevalence of both
smoking and impaired glucose regulation.
Fibrinogen. Fibrinogen levels were significantly
higher in the first-degree relatives than in control subjects
(Table II), and in smokers than in nonsmokers (geometric
mean, 3.12 g/L vs 2.87 g/L; P  .001). Bivariate analysis
showed significant correlation between Log10 fibrinogen,
age, and vWF levels. In the control group alone there were
additional correlations with BMI and diastolic blood pres-
sure (Table III). There was no difference in genotype
frequency at the B-455 polymorphism between relatives
(GG 107, GA 49, AA 7) and control subjects (GG 112, GA
44, AA 4) (2  1.173; 2 degrees of freedom (df); P 
.556). Nor was there an association between B-455 geno-
type and fibrinogen levels (relatives, GG 3.07, GA 2.95, AA
3.36 g/L, P .339; controls, GG 2.87, GA 2.85, AA 2.76
g/L, P 0.920). Multiple linear regression was performed
with Log10 fibrinogen as the dependant variable, and age,
smoking status, case type (relative vs control subject), and
vWF level as covariates. The final model accounted for
16.4% of variance in Log10 fibrinogen levels, with relative
status, current smoking status, age, vWF levels, and FVII:C
activity independently predicting Log10 fibrinogen levels
(Table IV). Adjusted fibrinogen levels were significantly
higher in first-degree relatives (geometric mean, 3.09 g/L;
anti-logged 95% confidence interval [CI], 2.99-3.18) than
in control subjects (2.95 g/L; 95% CI, 2.86-3.04; P 
.049).
Factor VII:C. FVII:C was significantly higher in
first-degree relatives than in control subjects (Table II).
There was no significant difference in FVII:C between
smokers and nonsmokers (mean, 111.4% vs 109.7%; P 
.570). FVII:C correlated with age and a number of
features of insulin-resistance syndrome, including BMI,
waist-hip ratio, Log10 systolic blood pressure, total cho-
lesterol, and Log10 triglyceride levels (Table III). In the
first-degree relatives alone there were additional correla-
tions with diastolic blood pressure, Log10 heart rate,
fasting glucose concentration, and Log10 HOMA. There
was no difference in genotype frequency at the factor VII
R353q polymorphism between first-degree relatives
(GG 131, GA 29, AA 3) and control subjects (GG 122,
GA 34, AA 2; 2  0.839; 2 df; P  .657). There was,
however, a significant association between R353q geno-
type and FVII:C, with a reduction in activity as the
number of A alleles increased (first-degree relatives, GG
119.2%, GA 106.7%, AA 96.0%, P  .046; control
subjects, GG 108.0%, GA 91.2%, AA 53.0%, P  .000).
nce in
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the dependant variable, and case type, nonpossession of
the r353q A allele (ie, GG vs GA or AA), and other
Table II. Clinical, biochemical, and hemostatic characteri
Relati
(N  1
Age (y) 38 (34,4
BMI (kg/m2) 26.3 (4.1)
Waist-hip ratio 0.90 (0.07
Systolic blood pressure (mm Hg) 135 (132
Diastolic blood pressure (mm Hg) 82 (11.5
ABPI 1.13 (0.08
Heart rate (bpm) 67.4 (65.5
Alcohol (units/wk). 20 (6,28
Current smoker (%) 73 of 165
Cholesterol (mmol/L) 5.77 (1.14
LDL (mmol/L) 3.68 (1.02
HDL (mmol/L) 1.23 (1.17
Triglyceride (mmol/L) 1.62 (1.47
0-Hour glucose level (mmol/L) 4.90 (4.70
2-Hour glucose level (mmol/L) 5.28 (5.01
IGR or diabetes (%) 22/165 (1
Fasting insulin (	m/L) 8.43 (7.82
HOMA 1.85 (1.70
Fibrinogen (g/L) 3.04 (2.93
FVII:C (%) 116.7 (28.5
vWF (iu/ml) 1.10 (0.45
Factor XIII A2B2 (	g/mL) 1.18 (0.28
Factor XIII B subunit (	g/mL) 1.11 (0.23
BMI, Body mass index; ABPI, ankle-brachial pressure index; LDL, low-dens
HOMA, estimated insulin resistance; FVII:C, factor VII clotting activity; vW
*Nonparametric data expressed as median (25th, 75th quartiles).
†Parametric data given as mean (SD).
‡Log10 normal data expressed as geometric mean (anti-logged 95% confide
§Categorical data expressed as a proportion (%).
Table III. Bivariate correlation coefficients for fibrinogen
Log 10 fibrinogen
Relatives
Control
subjects Rela
Age* 0.284 0.255 0.2
Body mass index 0.059 0.165 0.2
Waist-hip ratio 0.030 0.151 0.1
Log10 systolic blood pressure 0.017 0.079 0.1
Diastolic blood pressure 0.009 0.122 0.1
Log10 heart rate -0.046 0.142 0.2
Alcohol intake* -0.016 -0.010 -0.0
Cholesterol 0.146 0.119 0.2
Log10 HDL -0.078 -0.141 -0.0
Log10 triglycerides 0.017 0.141 0.3
Fasting glucose* 0.153 0.138 0.2
Log10 HOMA 0.128 0.134 0.2
Log10 fibrinogen 1.000 1.000 0.1
FVII:C (%) 0.130 0.178 1.0
Factor XIII A2B2 0.125 0.094 0.2
Factor XIII B subunit 0.252 0.220 0.3
Note that where both variables are normally distributed, values presented a
Spearman rank correlation coefficients () are given. For all data, P  .05 w
FVII:C, Factor VII clotting activity; vWF, von Willebrand factor; HDL, higcorrelates as covariates. The final model accounted for25.8% of variance in FVII:C levels (Table V). Adjusted
levels of FVII:C were significantly higher in first-degree
relatives (mean, 109.4%; 95% CI, 105.4-113.5) than in
of study groups
Control subjects
(N  165) P
40 (33,48) .304*
26.2 (3.8) .728†
0.90 (0.06) .455†
130 (128,132) .006‡
80 (11) .130†
1.13 (0.10) .766†
) 66.4 (64.7,68.1) .423‡
15 (6,30) .398*
) 51 of 165 (31%) .012§
5.22 (0.97) .000†
3.23 (0.89) .000†
) 1.29 (1.23,1.33) .050‡
) 1.34 (1.22,1.47) .005‡
) 5.00 (4.60,5.35) .662*
) 5.23 (5.02,5.44) .729‡
) 8/165 (4.8%) .012§
) 6.93 (6.58-7.30) .000‡
) 1.53 (1.44-1.62) .000‡
) 2.88 (2.79-2.96) .021‡
104.1 (21.4) .000†
1.06 (0.41) .475†
1.11 (0.29) .021†
1.01 (0.22) .000†
protein; HDL, high-density lipoprotein; IGR, impaired glucose regulation;
n Willebrand factor.
tervals).
I:C, and vWF
:C (%) Factor XIII A2B2 Factor XIII B subunit
Control
subjects Relatives
Control
subjects Relatives
Control
subjects
0.260 0.175 0.271 0.126 0.406
0.246 -0.043 0.214 0.194 0.301
0.183 -0.063 0.327 0.057 0.458
0.166 0.029 0.240 0.069 0.201
0.140 0.051 0.169 0.069 0.237
0.120 0.121 0.053 0.132 0.121
-0.024 0.164 0.164 0.143 0.037
0.238 0.157 0.360 0.310 0.292
0.209 0.020 0.020 0.020 -0.070
0.182 0.210 0.315 0.256 0.394
0.029 0.036 0.335 0.088 0.207
0.114 0.156 0.189 0.039 0.294
0.141 0.125 0.094 0.252 0.220
1.000 0.216 0.206 0.302 0.308
0.206 1.000 1.000 0.389 0.635
0.308 0.389 0.635 1.000 1.000
rson correlation coefficients (). Where one variable is nonparametric (*),
 0.160, P  0.01 where r  0.200, P  0.001 where r  0.256.
sity lipoprotein; HOMA, estimated insulin resistance.stics
ves
65)
3)
)
,137)
)
)
,69.3
)
(44%
)
)
,1.27
,1.78
,5.30
,5.58
3.3%
-9.08
-2.02
-3.15
)
)
)
)
ity lipo
F, vo, FVI
FVII
tives
23
17
58
87
85
41
15
86
03
29
77
17
30
00
16
02
re Peacontrol subjects (100.8%; 96.8-104.9; P  .001).
smoke
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cantly higher in the first-degree relatives compared with
control subjects (Table I) and in smokers compared with
nonsmokers (mean, 1.24 vs 1.09 	m/mL; P  .000).
FXIII A2B2 significantly correlated with a number of fea-
tures of insulin-resistance syndrome, including age, alcohol
intake, total cholesterol, Log10 triglyceride level, FVII:C,
Log10 HOMA, and the B subunit. Additional correlations
with BMI, waist-hip ratio, and Log10 systolic and diastolic
blood pressure were present in control subjects. The final
multiple linear regression model accounted for 31.5% of
variance (R2) in factor XIII A2B2 levels. Only the factor
XIII B subunit, current smoking, Log10 plasminogen-
activator inhibitor-1 triglyceride, and Log10 HOMA inde-
pendently predicted factor XIII A2B2 levels. There was no
difference in adjusted factor XIII A2B2 levels between
first-degree relatives (mean 1.16 	m/mL; 95% CI, 1.12-
1.20), and control subjects (1.15 ng/mL; 95% CI, 1.11-
1.19; P  .694).
Factor XIII B subunit. Factor XIII B subunit levels
were significantly higher in first-degree relatives than in
control subjects (Table II) and in smokers than in non-
smokers (mean, 1.10 vs 1.03 	m/mL; P .05). B subunit
levels correlated with a number of features of insulin-
resistance syndrome (Table III), including BMI, total cho-
lesterol, Log10 triglycerides, Log10 fibrinogen, FVII:C,
Log10 PAI-1, and factor XIII A2B2 levels in both study
Table IV. Multiple linear regression model for Log10 fibr
Parameter
Regression coefficient
(95% CI)
Final model
Relative status 0.02 (6.6505-3.8102)
Current smoker 0.03 (1.0102-4.9102)
Age (y) 1.4003 (3.1404-2.4803)
vWF antigen 6.3502 (2.6902-1.0001)
FVII:C 6.3004 (2.4402-1.0101)
R2  0.164 (adjusted R2  14.8).
vWF, von Willebrand factor; FVII:C, factor VII clotting activity.
*Change in fibrinogen (g/L) according to relative vs control status, current
and 10% increase in FVII:C.
Table V. Multiple linear regression model for FVII:C: Pa
Parameter
Regression coefficient
(95% CI)
Final model
Nonpossession A allele (M2) 17.55 (11.40-23.71)
Relative status 8.61 (3.36-13.86)
Cholesterol 3.97 (1.18-6.77)
Body mass index 0.81 (0.13-1.50)
Age (y) 0.30 (0.09-0.60)
Log triglycerides 11.60 (0.05-23.1)
R2  0.258 (adjusted R2  0.241).
FVII:C, Factor VII clotting activity.
*Change in FVII:C activity (%) according to relative vs control status, nonpo
mass index, and 10-year increase in age.groups. The final regression model accounted for 36.3% ofvariance in B subunit levels (Table VI). Adjusted factor XIII
B subunit levels were significantly higher in first-degree
relatives (mean, 1.08 ng/mL; 95% CI, 1.06-1.11) than in
control subjects (1.04 ng/mL; 95% CI, 1.01-1.07; P 
.024).
vWF. There was no significant difference in vWF levels
between first-degree relatives and control subjects. Only
age and Log10 fibrinogen independently predicted vWF
levels (  0.010, P  .001, and   0.719, P  .037; R2
 8.9%, respectively) in the final regression model.
DISCUSSION
This is the first study to show that “healthy” male
relatives of men with intermittent claudication cluster mul-
tiple clinical, biochemical, and metabolic risk factors for
atherosclerosis. The emphasis of this study was on throm-
botic risk, however, and our novel findings demonstrate
elevated plasma fibrinogen, factor VII, and factor XIII
levels in these subjects. Although case-control studies are
prone to bias and confounding, the robust method used for
our study reinforces the validity of our findings. First, the
presence of lower limb atherosclerosis in all probands was
determined both clinically and radiologically, thus provid-
ing an unequivocal family history of PAD. Second, to
ameliorate recruitment bias, we synchronously recruited
well-characterized and directly comparable first-degree rel-
atives and control subjects from the general population of
en: Parameter, effect size, and contribution to variance
Effect*
Contribution to
variance (%) P
16.4 .000
0.20 1.1 .049
0.30 2.5 .030
0.14 2.0 .120
0.07 2.5 .002
0.06 2.8 .001
r vs nonsmoker status, 10-year increase in age, 0.1 IU/mL increase in vWF,
ter, effect size, and contribution to variance
Effect*
Contribution to
variance (%) P
25.8 .000
17.3 7.8 .000
8.6 2.5 .001
4.0 1.9 .005
4.1 1.3 .020
3.6 1.0 .043
1.2 1.0 .049
ion of A allele, 1-mmol/L increase in cholesterol, 5-kg/m2 increase in bodyinograme
sssessWest Yorkshire. Ultimately 78% of all probands with an
ease in
rol sta
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study, and all study subjects had clinical CVD excluded
with validated and reproducible means. All laboratory as-
says were performed in duplicate, and our strict quality
control measures ensured excellent reproducibility. In ad-
dition, to mitigate against confounding we adjusted for a
comprehensive array of clinical, biochemical, and metabolic
risk factors. Despite these adjustments, the association be-
tween relative status and fibrinogen, factor VII, and factor
XIII B subunit levels remained significant. The indepen-
dent nature of this association may be explained by the
inheritance of independent genetic factors. Certainly heri-
tability studies suggest that between 33% and 44%, 53% and
62%, and 41% of variance in fibrinogen, factor VII, and
factor XIII B subunit levels, respectively, are due to genetic
factors.13,29,30 In our study genetic variation at the fibrin-
ogen B-455 or factor VII r353q polymorphisms did not
explain the observed differences in protein levels. Neverthe-
less, CVD is a polygenic disorder, and this study was not
powered as a primary gene association study. Undeter-
mined genetic factors may therefore modulate hemostatic
protein phenotype and hence vascular risk within our fam-
ilies. One limitation of our case-control design, however, is
inability to differentiate between the effects of genetics and
shared environment. “Unrecognized” environmental fac-
tors may therefore contribute to protein phenotype in our
study population. Furthermore, we cannot fully exclude
the presence of subclinical atherosclerotic burden with
questionnaire, electrocardiography, and ABPI alone, and
these factors may confound our observations. Ultimately
our final models explained 16.4%, 25.8%, and 36.3% of
variance in fibrinogen, FVII:C, and fctor XIII B subunit
levels, respectively, which is consistent with other stud-
ies.6,17-19 Consequently a significant proportion of inter-
subject variation remains unexplained, and may be due to
unknown environmental factors, underlying inflammation,
measurement error, or true random variation. Finally, we
acknowledge that family history was not the strongest
predictor of hemostatic protein levels in our study popula-
tion. Features of insulin-resistance syndrome were impor-
tant determinants of FVII:C and factor XIII B subunit
Table VI. Multiple linear regression model for factor XIII
variance
Parameter
Regression coefficient ()
(95% CI)
Final model
Factor XIII A2B2 0.337 (0.262-0.411)
FVII:C 1.2402 (3.8304-2.1003)
Body mass index 7.4603 (1.9803-1.2902)
Log10 triglyceride 0.109 (0.241-0.195)
Relative status 4.7802 (6.3803-8.9302)
R2  0.363 (adjusted R2  0.355).
FVII:C, Factor VII clotting activity.
*Change in factor XIII B subunit level (	g/mL) according to 1-	g/mL incr
in body mass index, 1-mmol/L increase in triglyceride, and relative vs contlevels, whereas fibrinogen was primarily influenced by age,smoking status, and other hemostatic parameters. These
data illustrate the complex interplay of genetic and environ-
mental factors that govern protein phenotype, although we
stress the importance of heritability studies when quantify-
ing genetic contribution.
Fibrinogen. Fibrinogen is a 340-kd glycoprotein syn-
thesised by hepatic parenchymal cells. Fibrinogen is de-
monstrable within the tunica intima of atherosclerotic
plaque, and the constant cycle of fibrin turnover has been
implicated in lesion progression.31 In healthy subjects ele-
vated fibrinogen independently predicts development of
PAD,4 AMI,5,6 and stroke.7 Fibrinogen is thus a powerful
pro-thrombotic marker, and this effect is independent of
blood viscosity.34 The mechanisms that underpin these
associations remain unclear, although abnormal fibrin gel
architecture is associated with AMI in young men.35 High
plasma fibrinogen levels are associated with enhanced factor
XIII activation rate and alteration in fibrin clot structure
and function.36 Consequently the high levels in our first-
degree relatives may have adverse cardiovascular implica-
tions. It is thus interesting that our findings parallel those in
other population subgroups at high risk, including the
healthy first-degree relatives of patients with severe CAD18
and type 2 diabetes.19 Fibrinogen is an “acute phase reac-
tant,” however, and the high levels seen during infection
and inflammation may be mediated by interleukin-6.37
Mounting evidence links inflammation to atherothrombo-
sis.38 The high fibrinogen levels in our relatives may there-
fore serve as a marker for underlying inflammation or
subclinical atherosclerosis. Although the ABPI is a valid and
reproducible means of detecting subclinical PAD,22 it is
only accurate in detecting flow-limiting stenoses and not
early plaque formation or minimal stenoses. The measure-
ment of subclinical atherosclerotic burden with carotid,
aortic, and femoral ultrasound scanning was, however, not
the primary purpose of this study, but will form the basis of
ongoing investigations.
Factor VII. Factor VII is synthesized by the liver,
circulates in the plasma at low levels, and is activated by
contact with tissue factor.39 Elevated FVII:C levels inde-
pendently predict for AMI in some4 but not all studies,2
bunit: Parameter, effect size, and contribution to
Effect size
Contribution to
variance (%) P
36.3 .000
0.34 15.8 .000
0.12 1.6 .005
0.04 1.4 .008
0.11 1.3 .012
0.05 1.0 .024
factor XIII A2B2 levels, 10% increase in FVII:C activity, 5.0-kg/m2 increase
tus.B suand may more specifically predict for fatal events.3 In the
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associated with development of intermittent claudica-
tion,32 but with symptoms developing in only 52 subjects
this study was most certainly underpowered. Elevated
FVII:C levels, however, predict for acute cardiovascular
events in patients with established PAD,40 and the presence
of elevated levels in our first-degree relatives may likewise
confer adverse risk. Although a causal atherothrombotic
role has yet to be established, similar findings are demon-
strable in the healthy first-degree relatives of patients with
type 2 diabetes19 but not severe CAD.18 The precise rea-
sons for these discrepancies remain obscure, although PAD
should be considered a marker for systemic atherosclerotic
burden. In our study about 45% of probands had concom-
itant CAD, whereas only 10% of Mill’s coronary probands
had symptomatic PAD. Consequently it may be appreci-
ated that our first-degree relatives were derived from a
proband population with advanced systemic atherosclero-
sis. It is thus plausible that familial mechanisms, including
those regulating FVII:C levels, may therefore be more
likely to be operative in patients with PAD. Finally, our data
support association between factor VII, insulin resis-
tance,41 and triglyceride level,42 as previously described.
The association between factor VII and relative status was
independent of these variables, however, which suggests
influence from independent genetic or environmental fac-
tors.
Factor XIII. Factor XIII circulates in plasma as an
inactive tetramer (factor XIII A2B2). The A subunit con-
tains the active motif, and is synthesised in the bone mar-
row, whereas the hepatic-synthesized B subunit acts as a
carrier protein, with up to 50% circulating in the free
dimeric form.43 After thrombin activation, factor XIII ca-
talyses the formation of stable fibrin clot with enhanced
mechanical strength and resistance to fibrinolysis.44 In-
creased plasma levels of fibrin polymers45 and abnormal
fibrin clot structure and function are present after AMI.35
Increased plasma fibrin stabilizing activity is demonstrable
in atherosclerotic PAD, and correlates with factor XIII
levels.46 More recently, elevated A and B subunit levels
have been shown in type 2 diabetes,6 severe CAD, and
AMI.7 Furthermore, factor XIII inhibition augments the
effect of tissue plasminogen activator (t-PA)–thrombolysis
in animal models.44,47 These data suggest that factor XIII
has a pivotal role in stable fibrin clot formation, and may
have a putative role in the pathogenesis of atherothrombo-
sis. In keeping with our data, elevated factor XIII subunit
antigen levels are present in the first-degree relatives of
patients with type 2 diabetes.6 Our data support an associ-
ation between factor XIII and underlying insulin resistance
as consistent with recent observations.6,17 Thrombotic risk
factors cluster in the presence of insulin resistance9, and
factor XIII may represent another dimension to this syn-
drome complex. The association between relative status
and factor XIII A2B2 levels was attenuated by adjustment
for the B subunit, insulin resistance, triglycerides, and
smoking. Thus differences in factor XIII A2B2 levels may be
partly mediated by insulin resistance, although our cross-sectional study design does not enable us to establish a
causal relationship. Conversely, association with the B sub-
unit was independent from other variables. Similarly only B
subunit levels are elevated in healthy first-degree relatives of
probands with severe CAD.17 Inasmuch as the B subunit
does not contain the active enzymatic site, the functional
consequences of our observations are uncertain. Like fi-
brinogen, the B subunit is synthesized by the liver, how-
ever, and the elevated B subunit levels found may simply
serve as a marker for chronic inflammation.
SUMMARY
This is the first study to demonstrate the clustering of
multiple atherothrombotic risk factors in healthy male rel-
atives of men with intermittent claudication. The emphasis
of this study was on thrombotic risk, however, and we have
shown increased levels of fibrinogen, factor VII, and factor
XIII in our population of first-degree relatives. These find-
ings are directly comparable with other population sub-
groups, including first-degree relatives of subjects with
CAD16-18 and type 2 diabetes,6,19 who are at high cardio-
vascular risk. Elevated hemostatic protein levels consis-
tently predict for cardiovascular risk in healthy subjects, and
our findings have identified a pre-thrombotic state in these
subjects. Recent data suggest a high prevalence of clinical
CVD and occult PAD in first-degree relatives of subjects
with premature PAD.14-15 Our data support the hypothesis
that this subgroup of the population is at high risk for CVD.
Further longitudinal studies are required, however, to ex-
amine the relationship between the pre-thrombotic state
and CVD. Once established, this may have major implica-
tions for both primary prevention and development of new
therapeutic strategies.
We thank Mr M. Gough, Mr M. I. Aldoori, Mr D. C.
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